Everest Group (EG)
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-09-14
$379.54+2.11%
Close 2026-09-14 · 1-day change
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-09-14
Research Workspace
Put EG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is contracting — down about 5% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 38%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEG's growth in specialty markets must continue to justify its current valuation. Revenue has been declining, with a recent earnings beat showing a year-over-year revenue drop of 11.8%. It trades at 0.9× price-to-book, below the peer median of 1.3×. This suggests the price reflects less growth than anticipated, as expectations look modest versus our view. A specific risk is the recent drop in financial performance, which fell to the bottom half of its industry. Peer multiples imply a price about 20% above where it trades. Our read is provisional.
Trailing returns as of 2026-09-14. EG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering EG (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for EG in the last 4 months.
Continue this research
Compare EG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financials (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put EG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
A quiet hurricane season supports growth in specialty markets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $379.54
The last 12 months of price, then the range of analyst 12-month targets from today’s $379.54.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Accelerate capital return to shareholders
Shelf registration supports capital return strategy.
Expands product portfolio, aligning with growth objectives.
Strengthens presence in ophthalmology, supporting growth strategy.
Commercialization agreement enhances product offerings.
Best-in-class BTK inhibitor enhances product pipeline.
Acquisition enhances market position in Colombia.
Sale of unit aligns with strategic focus.